Why GLP-1 Medications Don’t Work for Everyone — And What Patients Can Do
Written by Ravoke News Desk Growing Popularity of GLP-1 Treatments Medications known as GLP-1 receptor agonists have surged in use across the United States, helping people manage both Type 2
Written by Ravoke News Desk
Growing Popularity of GLP-1 Treatments
Medications known as GLP-1 receptor agonists have surged in use across the United States, helping people manage both Type 2 Diabetes and obesity. Drugs like Wegovy and Zepbound are now widely prescribed for weight loss, with recent estimates suggesting roughly 12% of U.S. adults are taking a GLP-1 medication.
Clinical data shows many users can lose between 5% and 15% of their body weight within a year. But for a significant group—up to 20%—these medications deliver little to no meaningful results.
Why Some People Don’t Respond
Researchers are increasingly finding that biology plays a major role in how individuals respond to GLP-1 drugs. Differences in genetics may influence how the body processes these medications, affecting appetite regulation, metabolism, and overall weight loss outcomes.
Other factors may also contribute, including hormone levels, lifestyle habits, and underlying medical conditions. This variability highlights a key issue in obesity treatment: no single therapy works universally.
How GLP-1 Drugs Work
GLP-1 medications mimic natural gut hormones that regulate hunger and digestion. They slow stomach emptying and signal the brain to feel full sooner, helping reduce overall calorie intake.
However, these drugs primarily target physical hunger—not necessarily the emotional or reward-driven aspects of eating, such as cravings for high-sugar or high-fat foods.
A Different Approach: Combining Treatments
New research suggests that pairing GLP-1 drugs with another medication, Contrave, may improve results for some patients.
Contrave is a combination of two drugs—naltrexone and bupropion—that work on the brain’s reward system. It targets areas responsible for cravings, pleasure from food, and compulsive eating behaviors.
By influencing dopamine pathways in the brain, Contrave can reduce the desire for comfort foods and make certain eating habits less rewarding. This complements the appetite-suppressing effects of GLP-1 medications.
Why Combination Therapy May Work Better
Experts say the combination approach addresses multiple drivers of weight gain at once:
- GLP-1 drugs reduce hunger and increase fullness
- Contrave helps control cravings and emotional eating
Together, they may provide a more complete strategy, particularly for people who struggle with binge eating or who have not achieved at least 5% weight loss using GLP-1 medications alone.
Obesity Treatment Is Not One-Size-Fits-All
Specialists in obesity care emphasize that weight management is complex and influenced by many factors, including genetics, environment, behavior, and mental health.
Because of this, personalized treatment plans are becoming increasingly important. Some patients respond well to a single medication, while others may require a combination of therapies, lifestyle changes, and ongoing medical support.
Frustration for Patients Who Don’t See Results
For patients who do not respond to GLP-1 medications, the experience can be discouraging. Many invest time, effort, and money into treatment, only to see limited progress.
Doctors note that it is not always possible to predict who will respond well to a specific drug. This uncertainty makes it essential to monitor progress closely and adjust treatment strategies when needed.
The Importance of Personalized Care
Medical experts recommend that patients work closely with healthcare providers to identify the most effective plan. This may include:
- Evaluating why a medication is not working
- Adjusting dosage or switching therapies
- Introducing combination treatments
- Addressing lifestyle and behavioral factors
Early intervention with a tailored approach can improve outcomes and help patients achieve more sustainable weight loss.
Looking Ahead: More Targeted Treatments
Ongoing research is focused on better understanding why some individuals respond differently to obesity treatments. Scientists hope to develop more targeted therapies based on genetics and metabolic profiles.
As knowledge evolves, the future of weight loss treatment is expected to shift toward precision medicine—where therapies are customized to each individual rather than applied broadly.
Bottom Line
GLP-1 medications have transformed weight loss treatment for many, but they are not effective for everyone. For those who do not see results, combination therapies like adding Contrave may offer a promising alternative.
Health experts stress that obesity is a complex condition requiring flexible, individualized care—and new strategies are continuing to emerge to meet that need.
